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ABSTRACT  
Background and objective  
People who inject drugs (PWID) account for over half of new HIV infections in Eastern 
Europe and central Asia, where opioids continue to be the dominant illicit drugs 
injected. Stimulants including amphetamines (ATS) have been associated with HIV 
infection risk in several settings. We sought to examine whether primary ATS injection 
was associated with greater HIV risk, compared to opioid injection in two European 
locales with significant HIV epidemics.  
Methods  
PWID in Kohtla-Järve and St. Petersburg were recruited in respondent driven sampling 
in 2012-2013. Survey data on demographic characteristics, service use, injecting and 
sexual risk behaviours, and HIV-status (and HCV in Kohtla-Järve) were compared 
between primary opioid and ATS injectors using logistic regression models.  
Results   
Of 591 injectors recruited in Kohtla-Järve and 811 in St. Petersburg, 195 (33%) and 27 
(4%) primarily injected ATS in each city. In both cities, ATS injectors were younger 
than opioid injectors, initiated injection later, injected less frequently and were more 
likely to have been paid for sex. In both cities, PWID had high levels of multiple sex 
partners. In Kohtla-Järve, ATS-injectors had lower odds of back-loading and greater 
odds of polydrug use than opioid-injectors. In St. Petersburg, where over half of PWID 
reported unsafe sharing practices, ATS-injectors were less likely to report these 
practices. ATS-injection was negatively associated with being HIV positive in Kohtla-
Järve (aOR=0.6; 95%CI: 0.5-0.8) and St. Petersburg (aOR=0.3; 95%CI: 0.1-0.7). ATS-
injection was negatively associated with HCV-reactivity in Kohtla-Järve (aOR=0.5; 
95%CI: 0.3-0.6).  
Conclusions 
In both locations, primary ATS injection was associated with lower  injecting risk 
behaviours, lower HIV status and being paid for sex compared to opioid injection. 
Targeted services are needed for ATS injectors, to increase contact with interventions 
and reduce sexual and injecting risk. Harm reduction services, including sexual risk 
reduction, need to be expanded for all PWID in St. Petersburg.  
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INTRODUCTION 
People who inject drugs (PWID) were estimated to account for 51% of new human 
immunodeficiency virus (HIV-1) infections in Eastern Europe and central Asia in 2014, 
a region with the fastest growing HIV epidemic associated with injection drug use 
globally (United Nations Joint Programme on AIDS, 2016; United Nations Office on 
Drugs and Crime, 2016).  
Opioid injection has been the main driver of HIV epidemics in Estonia and the Russian 
Federation, where over half of PWID in Kohtla-Järve (Estonia) and St. Petersburg 
(Russian Federation) were seropositive in 2012 (Table 1) (El-Bassel, Strathdee, & Sadr, 
2013; Jolley, et al., 2012; United Nations Joint Programme on HIV and AIDS, 2013; 
Uuskula, Raag, et al., 2015; Walsh & Maher, 2013). Kohtla-Järve and St. Petersburg are 
situated on the Baltic Sea, on the northern part of two major heroin trafficking corridors 
linking Afghanistan to the heroin markets of Western Europe (United Nations Office on 
Drugs and Crime, 2012, 2015b). HIV epidemics in both cities have followed similar 
trajectories, driven by transmission among PWID but they differ on several contextual 
factors shown in Table 1.  
Table 1. HIV epidemic, context and response in Kohtla-Järve (Estonia) and St. Petersburg (Russia) 
Indicator All Estonia Kohtla-Järve St. Petersburg 
HIV incidence (per 100 person years) 20.7 per 100 PY (2005) 
(Uuskula, Des Jarlais, Raag, Pinkerton, & Feelemyer, 
2015) 
7.5 per 100 PY (2011)(1) 
22 per 100 PY (2012)(1) 4.5 per 100 PY (2009) (Andrei P. 
Kozlov, et al., 2006) 
7.2/100 person-years (A. P. Kozlov, et 
al., 2016) 
HIV Prevalence 52% (United Nations Joint Programme on HIV and 
AIDS, 2013) 
63% (95%CI: 56%-67%) 
(Uuskula, Raag, et al., 2015) 
59% (95%CI: 52%-59%) 
(Uuskula, Raag, et al., 2015) 
PWID population size estimate 5,362 (range: 3,906–9,837) (Uuskula, 
Rajaleid, Talu, Abel-Ollo, & Des Jarlais, 2013) 
XX 83,120 (95%CI:77,320 -88,920) 
(Heimer & White, 2010) 
% of population who inject drugs 
 
2.0% (95%CI: 1.4–5.0%) (2008) 
(Uuskula, et al., 2013) 
0.9% (95%CI: 0.7–1.7%)(2009) 
(Uuskula, et al., 2013) 
XX 5.5% (2008) (Heimer & White, 2010) 
Needle/syringe services (start year) 1997 2004 NSPs not endorsed 
Needle/syringe services (n, year) 22 outreach, 14 fixed NSP (2014) 
(National Institute for Health Development, 2015) 
XX XX 
Clean syringes per PWID per year 125 syringes/PWID per year (2011) XX XX 
Services provided by NGOs, government health services NGOs NGOs 
    
Drug substitution (start year) 2001 2004 OST illegal 
Type of drug treatment Opiate substitution Opiate substitution Detoxification only (21 days) 
Coverage (%, n and year) 15% of PWID (n=919, 2014)(3) XX XX 
Services provided by NGOs, clinics NGOs, clinics Centralized, in-patient 
*Reference population for Estonia aged 15-44 years old; for St Petersburg aged 20-45 years old. HIV= Human Immune deficiency 
virus. PWID people who inject drugs. PY= person-years. NSP= Needle and Syringe Programme. NGO= Non-governmental organisation. 
Notably, evidence-based harm reduction interventions including needle and syringe 
programmes (NSP) and opiate substitution treatment (OST) were introduced early in 
Kohtla-Järve (Estonia Ministry of Health, 2014; Mathers, et al., 2010), whereas in St 
Petersburg they are not endorsed by the government, OST remains illegal and clean 
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needles and syringes are only provided by a few NGOs (Louisa Degenhardt, et al., 
2014; European Monitoring Centre for Drugs and Addiction, 2015).  
In both settings, most PWID injected heroin and synthetic opioids manufactured by 
illicit laboratories, namely fentanyls in Kohtla-Järve (introduced in Estonia following a 
heroin shortage in 2000) and methadone in St Petersburg (Eritsyan, et al., 2013; Grund, 
Zabransky, Irwin, & Heimer, 2009; Heimer, Lyubimova, Barbour, & Levina, 2015; 
Platt, et al., 2006). Estonia has reported one of the highest prevalence of amphetamine 
type stimulant (ATS) use in Europe (European Monitoring Centre for Drugs and Drug 
Addiction & Europol, 2012; United Nations Office on Drugs and Crime, 2014) and data 
suggest that ATS has emerged as a major secondary drug among PWID in Kohtla-Järve 
and St. Petersburg (European Monitoring Centre for Drugs and Drug Addiction, 2010; 
Grund, et al., 2009; United Nations Office on Drugs and Crime, 2015a). However, it is 
not clear whether ATS injection has any relevance on risk behaviours and HIV 
epidemics in these settings.  
ATS are psychostimulants that are relatively easy to synthesize and increasingly 
injected in settings previously dominated by opiates (Bao, et al., 2012; Booth, et al., 
2008; Grund, et al., 2009; Hayashi, et al., 2011; Martin, et al., 2010). ATS have been 
associated with greater sexual risk, including multiple sex partners and unprotected sex, 
which may compound the risks of HIV acquisition among PWID (Baker, Kochan, 
Dixon, Wodak, & Heather, 1994; Booth, et al., 2008; Shane Darke, Kaye, McKetin, & 
Duflou, 2008; Gleghorn, Marx, Vittinghoff, & Katz, 1998; Fred Molitor, et al., 1999; F. 
Molitor, Truax, Ruiz, & Sun, 1998). ATS injection has been associated with more 
frequent injecting, needle/syringe sharing and HIV infection in settings where PWID 
also injected other drugs (Braine, Des Jarlais, Goldblatt, Zadoretzky, & Turner, 2005; 
Crofts & Aitken, 1997; Hayashi, et al., 2011; Andrei P. Kozlov, et al., 2006; Tavitian-
Exley, et al., 2017) but not when stimulants were reported as primary drug (Booth, et 
al., 2008; Kral, Bluthenthal, Booth, & Watters, 1998; Swe & Rashid, 2012; Talu, et al., 
2010). Few studies have examined drug use patterns by main drug injected and their 
potential association with risk behaviours and HIV and HCV infection in Eastern 
European settings (Buster, et al., 2009; Folch, Merono, & Casabona, 2006; Harrell, 
Mancha, Petras, Trenz, & Latimer, 2012; Hayashi, et al., 2011; Hilary Klee, Faugier, 
Hayes, Boulton, & Morris, 1990; Ross, Darke, & Hall, 1997; Tavitian-Exley, 
Vickerman, Bastos, & Boily, 2015) and the potential relevance of ATS injection in these 
epidemics remains unclear (European Monitoring Centre for Drugs and Drug Addiction, 
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2010; European Monitoring Centre for Drugs and Drug Addiction & Europol, 2011; 
European Monitoring Centre for Drugs and Drug Addiction & Škařupová, 2014).  
Our aim is to assess whether primarily injecting ATS, as compared to opioids (heroin, 
synthetic heroin or methadone), is associated with increased injecting and sexual risk 
behaviours, and HIV status among PWID in Kohtla-Järve (Estonia) and St. Petersburg 
(Russian Federation), two East European locales with significant and epidemiologically 
similar HIV epidemics.  
METHODS 
Study population 
Integrated biological and behavioural surveys (IBBS) of HIV prevalence were 
conducted among PWID in Kohtla-Järve between May and July 2012, and in St. 
Petersburg from November 2012 to June 2013. Both surveys have been reported on and 
described previously (Cepeda, et al., 2015; Dukhovlinova, et al., 2015; Heimer, et al., 
2015; Tavitian-Exley, et al., 2017; Uuskula, Raag, et al., 2015) and used comparable 
recruitment criteria and respondent-driven sampling (RDS) survey methodology. 
Briefly, RDS starts with a diverse sample of seeds (6 seeds in Kohtla-Järve and 12 seeds 
in different districts of St. Petersburg, subsequently increased to 16 to cover key districts 
and compensate for unproductive seeds). Seeds were selected through needle/syringe 
programmes (NSP), to represent a range of demographic and drug profiles, and 
interviews and testing were conducted in fixed (Kohtla-Järve) and mobile clinics (St 
Petersburg). Each seed and subsequent participants was given an opportunity to recruit 
up to three PWID until a predetermined sample size was reached. Men and women aged 
18 years or over, who had injected drugs in the past 30 days, lived in Kohtla-Järve or St. 
Petersburg and provided informed consent for the study were eligible. Eligibility was 
verified by the presence of injection marks and questions on injection practices before 
the start of the interview.   
Measures 
Information on demographic and social factors, injection and sexual risk behaviours, 
and access to harm reduction services were recorded by trained fieldworkers in a 
structured confidential interviewer-administered questionnaire, using standardised study 
items and questions from established survey instruments (e.g. WHO Drug Injecting 
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study Phase II survey v2b) (Des Jarlais, Perlis, Stimson, Poznyak, & Collab, 2006; 
Uuskula, Raag, et al., 2015).  
HIV, HCV and HSV status 
HIV sero-status was assessed using an HIV Antigen/Antibody Combo Assay (ADVIA 
Centaur, Siemens Healthcare Diagnostics) and HIV I/II Score line assay confirmatory test 
(INNO LIA, Fujirebio Europe) in Kohtla-Järve; rapid oral HIV testing was conducted in St. 
Petersburg using OraQuick ADVANCE® Rapid HIV-1/2 Antibody Tests (OraSure 
Technologies Inc.) and confirmed at the City AIDS Centre (Uuskula, Raag, et al., 2015). In 
Kohtla-Järve only, HCV and Herpes Virus Simplex (HSV) reactivity were measured 
using commercially available kits for antibodies to HCV (Murex anti-HCV v 4.0) and 
HSV-2 (HSV-2 IgG ELISA, IBL International GmbH). 
The primary drug injected was categorised into mutually exclusive groups of primary 
ATS or primary opioid-injectors, based on the survey item main drug injected in the 
past 4 weeks. Injectors reporting no or “other” primary drug were compared with the 
rest of the sample and examined in descriptive analysis (and excluded in regression 
modelling).  
Demographic and contextual variables 
Demographic and contextual variables included age, sex, ethnicity, education completed 
(basic education/secondary and above), main source of income, living arrangements 
(stable/unstable), past month contact with an NSP, past year drug treatment (opioid 
substitution in Kohtla-Järve; any drug treatment in St. Petersburg) and having needles or 
syringes confiscated by the police.  
Injecting and sexual risk behaviours 
The behavioural variables examined included injecting-risk (using a 30 day recall 
period), sexual-risk behaviours (using a 6 month recall period) and serological markers 
for HIV (and in Kohtla-Järve only, HCV and HSV). Injecting behaviours of interest 
were past month injecting frequency (≥daily injecting vs. <daily injecting), intensity of 
injection on the last day injected (≥ 2 injections/day vs. <2 injections/day), injecting 
with used needles/syringes (sharing), sharing drug paraphernalia, back-loading (filling a 
syringe from a used syringe) and polydrug use (injecting a main drug and at least one 
other drug in the last month). Sexual risk behaviours included having a sex partner 
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(regular or casual) who injected drugs, having been paid for sex (i.e. receiving money or 
drugs for sex ever), multiple sex partners (≥ 2 sex partners in last 6 months) and 
consistent condom use (i.e. always) with sex partners. The variable “any sex in the last 
six months” was used to exclude non-sexually active PWID.  
Statistical analyses  
Descriptive statistics are presented for Kohtla-Järve and St. Petersburg separately (RDS-
adjusted estimates, using RDS-II sampling weights are presented in supplementary 
material) (Volz & Heckathorn, 2008; Volz, et al., 2012; White, et al., 2015). 
Two sets of logistic regressions were performed. The first set examined the 
determinants of ATS- and opioid-injection (dependent variable). In the second set, we 
assessed whether ATS (independent variable) was associated with a) injecting-risk 
behaviours, b) sexual-risk behaviours, and c) HIV, HCV and HSV prevalence. For both 
sets of regressions, we generated univariate and multivariable estimates (Kirkwood, 
2003 ; UCLA Statistical Consulting Group, 2015). Results for the multivariable 
regressions were adjusted for age, sex, education, living arrangements, duration of 
injecting (and for contact with NSP and drug treatment in the second set of regressions). 
These variables were judged to be important potential confounders, based on published 
evidence and our conceptual framework (Supplementary material: Figure S.1) (Lemstra, 
Rogers, Thompson, Moraros, & Buckingham, 2012; Marshall, et al., 2008; Marshall, et 
al., 2011; Poundstone, Strathdee, & Celentano, 2004; Tavitian-Exley, 2016). Correlated 
variables were examined for collinearity and omitted from the model if variance 
attributed to collinearity (VIF) was > 2.5). A complete case analysis was used and 
observations with missing values were omitted. Odds ratios (OR) with 95% confidence 
intervals (95%CI) were calculated while also adjusting for clustering of observations by 
recruitment seed (Kirkwood, 2003 ). Clusters were defined by a recruitment chain 
started by a given seed to account for the possibility that participants may be more likely 
to recruit other PWID with similar characteristics. This was achieved using the svy 
command in Stata (v.13.1) as in univariate analysis (Hosmer, 2000; Kirkwood, 2003 ; 
StataCorp., 2013; UCLA Statistical Consulting Group, 2015). Sampling weights were 
not taken into account in the regressions as their use is often unwarranted for causal 
inference (Solon, Haider, & Wooldridge, 2013). 
Ethics 
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Ethical approval was obtained from the Ethics Review Board of the University of Tartu 
(Estonia), the Institutional Review Board at NGO Stellit in St. Petersburg (Russian 
Federation), and the Human Investigation Committee at Yale University (USA). 
RESULTS 
Characteristics of study sample 
Our study included 591 PWID in Kohtla-Järve and 811 in St. Petersburg (Table 2; 
supplementary material: Table S.1). In both cities, the majority of PWID were male, 
Russian-speaking or reporting stable living conditions (Table 2; Table S.1). However, 
more PWID in Kohtla-Järve were under the age of 30 and salaried or with a regular job 
than in St. Petersburg.  
The primary drug commonly injected by PWID in both cities was a synthetic opioid (i.e. 
illicitly-manufactured fentanyl congeners in Kohtla-Järve; heroin and methadone 
produced in illicit laboratories in St. Petersburg) while ATS was the second most 
common drug class. Opioids were the primary drug for 61% of PWID in Kohtla-Järve 
and 96% in St. Petersburg; ATS was the main drug for 33% in Kohtla-Järve and 4% in 
St. Petersburg (6% of PWID in Kohtla-Järve had another or no primary drug). 
More PWID had been in contact with a needle and syringe programme in the past six 
months in Kohtla-Järve (82%) than in St. Petersburg (16%) and over half had ever 
received some form of attention for substance use disorder (Table 2). Substitution 
treatment was reported by 13% of PWID in Kohtla-Järve and detoxification by 11% in 
St. Petersburg in the past 12 months. Similar proportions of PWID had needles/syringes 
confiscated by the police in the last six months in both cities but more PWID reported 
ever being incarcerated in Kohtla-Järve (55%) than in St. Petersburg (34%). 
The majority of PWID in both cities had injected for more than 5 years with a mean age 
at first injection just under 19 years (Table S.1). Past-month injection risk behaviours 
were lower in Kohtla-Järve and up to nine times less frequent than in St. Petersburg. 
Past month polydrug use (injection of main and other drug) was equally widespread in 
both cities (47% and 41%). Fewer PWID in Kohtla-Järve had injected at least daily 
(24%) than in St. Petersburg (36%), shared needles and syringes (6% and 58%), filled 
from a used syringe (6% and 53%) or shared drug paraphernalia (7% and 68%). 
Over three quarters of PWID in both cities had sexual intercourse in the last 6 months 
and over half had a sex partner who injected drugs (55% in Kohtla-Järve and 58% in St. 
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Petersburg). Over a third of PWID had multiple sex partners (34% and 49%) and 7% in 
Kohtla-Järve and 4% in St. Petersburg, respectively, had ever been paid for sex. Close to 
half of PWID always used condoms with casual partners in Kohtla-Järve (58%) and St. 
Petersburg (48%). Due to the high non-response rate (>50%) for some sexual risk 
behaviours in Kohtla-Järve, results for this city were not shown given the high 
likelihood of bias; we only analysed the effect of ATS- or opioid-injection for those 
variables in St. Petersburg (Table S.1). More than half of PWID tested positive for HIV 
in Kohtla-Järve (61%) and in St. Petersburg (56%). HCV and HSV reactivity, measured 
in Kohtla-Järve only, was 75% and 32%, respectively. 
Associations between primary ATS injection and injecting and sexual risk 
behaviours and serology in Kohtla-Järve 
Determinants of ATS injection 
Determinants of primary ATS injection are presented in Table 3. In Kohtla-Järve, ATS 
injectors were younger than opioid injectors with greater odds of being under 30 years 
of age (adjusted Odds Ratio (aOR) =2.1; 95%CI: 1.4-3.2) and of later initiation to 
injection (aOR: 1.1; 95%CI: 1.0-1.4) than their opioid-injecting peers. The groups did 
not differ on other demographic characteristics. ATS injectors had lower odds of past-
year drug treatment (aOR=0.5; 95%CI: 0.3-0.9), past-month contact with an NSP 
(aOR=0.2; 95%CI: 0.2-0.6), having needles/syringes confiscated by the police 
(aOR=0.3; 95%CI: 0.1-0.8) and incarceration (aOR=0.3; 95%CI: 0.2-0.5). They had 
higher odds of obtaining clean needles/syringes from a pharmacy than an NSP (aOR: 
4.9 (95%CI: 3.5-6.9). 
Associations with injecting risk behaviours  
Primary ATS injection was associated with a number of injecting risk behaviours (Table 
4). ATS injectors were more likely to have injected for less than 5 years (aOR=3.5; 95% 
CI: 1.9-6.2) (Table 4). ATS injection was negatively associated with frequent injecting 
(aOR=0.3; 95%CI: 0.2-0.6), lifetime needle/syringe-sharing (aOR= 0.3; 95%CI: 0.2-
0.5) and back-loading (aOR= 0.4; 95%CI: 0.2-0.8) and positively associated with 
polydrug use (aOR=2.0; 95%CI: 1.1-3.5). Past month unsafe sharing practices such as 
sharing needles/syringe and drug paraphernalia were generally lower among primary 
ATS injectors but did not reach statistical significance (Table 4). 
Associations with sexual risk behaviours 
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One third of PWID reported multiple sex partners with no significant difference 
between primary ATS- and opioid-injectors; however ATS injectors had greater odds of 
ever being paid for sex (aOR=2.6; 95%CI: 1.2-5.7)(Table 5). 
Associations with HIV, HCV and HSV prevalence 
Primary ATS injectors in Kohtla-Järve had lower odds of testing positive for HIV 
(aOR=0.6; 95%CI: 0.5-0.8) and having antibodies to hepatitis C (aOR=0.5; 95%CI: 0.3-
0.6) in multivariate analysis, compared to primary opioid injectors (Table 6). HSV-2 
antibody status was not associated with ATS injection. 
Associations between primary ATS injection and injecting and sexual risk 
behaviours and HIV in St. Petersburg 
Determinants of ATS injection 
In St. Petersburg, primary ATS injectors had higher odds of being under 30 years of age 
(aOR=6.8; 95%CI: 2.8-16.5), female (aOR=1.7; 95%CI: 0.7-4.1), later initiation to 
injection (aOR: 1.3; 95%CI: 1.1-1.4) or having unstable living arrangements (aOR=2.2; 
95%CI: 1.0-4.6) than opioid injectors (Table 3). Contact with NSP and drug treatment 
were very low in St. Petersburg and did not differ between ATS- and opioid-injectors. 
However ATS injectors had greater odds of obtaining needles and syringes from sources 
other than an NSP (e.g. from friends, other PWID, a drug dealer or in the street) 
(aOR=35; 95%CI: 2.7-472) and lower odds of having been incarcerated and having 
needles/syringes confiscated compared to opioid injectors.  
Associations with injecting risk behaviours 
Primary ATS injectors were more likely to report fewer than 5 years of injecting 
(aOR=8.3; 95%CI: 2.2-31.6)(Table 4). Several injecting risk behaviours were negatively 
associated with ATS injection. Primary ATS injectors had lower odds of daily or more 
frequent injecting (aOR=0.2; 95%CI: 0.1-0.9), injecting more than twice a day (aOR: 
0.3; 95%CI: 0.1-0.6), sharing needles and syringes (aOR=0.2; 95%CI: 0.1-0.6), filling a 
syringe from a used syringe (aOR=0.2; 95%CI: 0.1-0.5) and sharing drug paraphernalia 
(aOR=0.3; 95%CI: 0.1-0.6) than opioid injectors. Polydrug use was frequent among 
both ATS- and opioid-injectors but did not differ significantly between the two groups.  
Associations with sexual risk behaviours 
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Almost half of PWID in the Russian city reported multiple sex partners, with no 
significant difference between ATS- and opioid-injectors (Table 5). In multivariate 
analysis, ATS injectors had greater odds of being paid for sex (aOR=5.2; 95%CI: 1.0-
27.0) and using condoms consistently with casual sex partners (aOR=8.0; 95%CI: 1.1-
60.0).  
Associations with HIV prevalence 
Primary ATS injectors in St. Petersburg had lower odds of testing positive for HIV than 
PWID injecting opioid (aOR=0.3; 95%CI: 0.1-0.7)(Table 6). HCV and HSV serology 
were not collected in St. Petersburg. 
DISCUSSION 
We compared risk behaviours and HIV status among self-identified primary ATS-
injectors and opioid-injectors in two settings with severe epidemics of drug use and 
HIV. Our results suggest that, in both locations, PWID primarily injecting ATS 
consistently differed on demographic characteristics and reported less or equally risky 
injecting behaviours compared to those who mainly injected opioids. ATS injectors in 
both cities were younger but started injecting later than opiate injectors, were more 
likely to report less than 5 years’ injecting and generally at earlier stages in their drug 
injecting careers. The younger age and later onset of injecting among ATS injectors, 
suggested the emergence of a different group of PWID who may be at earlier stages of 
drug dependence and injected less frequently than their opioid-injecting peers. 
In St. Petersburg, contact with NSPs was generally low and did not differ between the 
two groups; there primary ATS injectors were less likely to have injected with used 
needles/syringes, shared drug paraphernalia or back-loaded than opiate injectors.  
However in Kohtla-Järve, where harm reduction services are established, ATS injectors 
were significantly less likely than opiate injectors to have had contact with NSPs and 
reported similar prevalence of sharing needles/syringes or drug paraphernalia but were 
less likely to back-load than opiate injectors. Although the cross-sectional nature of our 
study precludes attributing causality, it is possible that harm reduction services in 
Kohtla-Järve (including OST) contributed to reducing injecting risk behaviours among 
opiate injectors thus “levelling” injecting risk between the two groups in this city.  
Our findings are generally consistent with those of studies, where self-reported primary 
ATS injection was associated with younger age and fewer years of injecting among 
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PWID in Australia, the USA, Ukraine and elsewhere in Estonia (Booth, et al., 2008; 
Braine, et al., 2005; Fairbairn, et al., 2007; Kaye & Darke, 2000; Talu, et al., 2010) and 
where primary ATS injectors reported similar or lower frequency of injection (Booth, et 
al., 2008; Braine, et al., 2005; Shane Darke, et al., 2008; Gleghorn, et al., 1998; Kaye & 
Darke, 2000; Maher, et al., 2007; Talu, et al., 2010) and similar frequency of needle and 
syringe-sharing than opiate injectors (Gleghorn, et al., 1998; Kaye & Darke, 2000; Talu, 
et al., 2010).  However the lower or equal injecting risk behaviours reported by primary 
ATS injectors in our study contrast with findings from studies where ATS injection was 
reported but not as primary drug and occurred in the presence of other injection drugs 
such as heroin (Braine, et al., 2005; Crofts & Aitken, 1997; Hayashi, et al., 2011; Andrei 
P. Kozlov, et al., 2006; Tavitian-Exley, et al., 2017). 
Both ATS-injectors and opioid-injectors in this study reported similarly high prevalence 
of sexual risk, including multiple sex partners, however primary ATS injectors were 
more likely to have ever been paid for sex. ATS can be used to increase energy, 
stamina, libido and reduce social and sexual inhibition and injection often occurs with 
peers or sexual partners, possibly generating more needle-sharing opportunities (S. 
Darke, Ross, Cohen, Hando, & Hall, 1995; H. Klee, 1993). Several other studies of 
PWID also found positive associations between ATS injection and multiple sex 
partners, unprotected sex and trading sex for money or drugs (Lorvick, Martinez, Gee, 
& Kral, 2006; Fred Molitor, et al., 1999).  
The frequency of sexual risk in both cities and possible intersection with sex work 
highlight the potential for sexual transmission of HIV, and an unmet need to engage 
diverse PWID sub-groups with prevention and risk reduction messages emphasising 
sexual as well injecting risks (Lorvick, et al., 2006; F. Molitor, et al., 1998; Rondinelli, 
et al., 2009). The prevalence of polydrug use was similarly high in both groups and 
cities, and associated with ATS injection in Kohtla-Järve.   
Finally, HIV prevalence and HCV in Kohtla-Järve, were lower among ATS- than 
opioid-injectors, consistent with their shorter, cumulative exposure to risk, resulting 
from younger age and later onset of injecting (Andrei P. Kozlov, et al., 2006; Martin, et 
al., 2010). These differences in HIV status remained after adjusting for factors such as 
injecting duration, suggesting that other determinants also play a role. Primary ATS 
injectors are nevertheless vulnerable to HIV acquisition as a result of their age (and 
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gender in St. Petersburg), high prevalence of sexual risk behaviours and low contact 
with harm reduction services (i.e. NSP and drug substitution treatment in Kohtla-Järve). 
The propensity of ATS injectors in Kohtla-Järve to obtain clean needles and syringes 
from pharmacies rather than NSPs when the majority of PWID in the sample were in 
contact with harm reduction services, also suggests they were not being reached 
(Vorobjov, et al., 2009). Furthermore, the lower odds of substitution treatment among 
ATS injectors in Kohtla-Järve, may be explained by the provision of methadone, 
intended for opioid (and not ATS) use disorders. Opioid-based substitution treatment 
has shown to reduce injecting behaviours and HIV infection among opioid users, and 
supports adherence to highly active anti-retroviral therapy (HAART) but no proven 
pharmacological treatment exists yet for ATS injectors (Ahamad, et al., 2015; 
MacArthur, et al., 2012; World Health Organization, 2013). Still, where ATS use is 
prevalent, services that are tailored to the different demographic characteristics and 
needs of ATS injectors, and include psychosocial interventions, need to be integrated to 
harm reduction programmes (Mehrjerdi, Abarashi, Noroozi, Arshad, & Zarghami, 2014; 
United Nations Office on Drugs and Crime, 2010). The problem of ATS injection in 
these cities, and globally, requires effective low-threshold services able to engage 
injectors who, are young and/or female, do not fit “conventional” drug use profiles 
associated with heroin and neither seek nor desire contact with services focused 
primarily on opioid injectors (Lorvick, et al., 2006; Pates, 2013; Shearer, Sherman, 
Wodak, & Van Beek, 2002; Vorobjov, et al., 2009). 
Moreover, while few studies have looked at the life course of drug use among primary 
ATS injectors, especially in resource-limited settings (Brecht, Huang, Evans, & Hser, 
2008), longitudinal and qualitative research would help to understand how primary 
ATS-injection and associated behavioural risks evolve over time. Consistent and 
systematic drug monitoring would also contribute to better understanding heterogeneity 
among PWID. 
Several limitations need to be acknowledged. First, our findings may only be 
generalizable to other PWID populations in Estonia or the Russian Federation. Second, 
obtaining standard probability samples of PWID populations is challenging due to the 
hidden nature of this group, their stigmatised behaviours and the absence of a sampling 
frame. Although RDS surveys have demonstrated the ability to reach such hidden 
population sub-groups, the representativeness of our samples cannot be verified (Abdul-
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Quader, et al., 2006; Heckathorn, 1997; Lisa G Johnston & Sabin, 2010). Third, 
information on injecting and sexual risk behaviours was collected through self-reports 
and social desirability bias may affect the results. Self-reporting using interviewer-
administered questionnaires has shown reliability in several studies and a 30-day period, 
as was used in this study, has shown to produce reliable recall on drug use and injecting 
behaviours among PWID (Shane Darke, 1998; Des Jarlais, et al., 1999; Napper, Fisher, 
Reynolds, & Johnson, 2010). Additionally, the small number of ATS injectors in St. 
Petersburg and wide confidence intervals limited analyses for this city. Finally, given 
the high prevalence of polydrug use in this population, dynamic nature of drug use and 
shorter recall, it is also conceivable that misclassification may have occurred between 
ATS-and opioid-injectors thus leading to possible bias. However, non-differential 
misclassification of the exposure generally biased the inferences towards the null and if 
this is the case, our results could be considered conservative (Dosemeci, Wacholder, & 
Lubin, 1990; Kirkwood, 2003 ).  
The strengths of this study include its large sample size and comparison in two Eastern 
European locations reporting a high prevalence of HIV and injection of different drug 
classes. Recruitment of two large and diverse PWID samples was facilitated by the use 
of RDS and reported according to the STROBE-RDS statement (L. G. Johnston, et al., 
2016; White, et al., 2015). We systematically compared self-identified PWID injecting 
different drug classes, using consistent definitions, study methods and tested tools, and 
highlighted important differences, consistent across sites, between primary ATS- and 
opioid-injectors, of relevance to policy and programmes. 
Primary ATS injectors reported lower or similar injecting risk behaviours, lower HIV 
prevalence than opioid injectors and engaged less with services. Both groups had high 
levels of multiple sex partners but primary ATS injection was associated with paid sex, 
suggesting overlaps between injecting and sexual risk. Low threshold services with 
interventions (e.g. behavioural) targeting the needs of young stimulant injectors are 
needed to increase their contact with services and reduce sexual risk behaviours. The 
coverage of harm reduction services, including sexual risk reduction, needs to be 
increased significantly in St. Petersburg for all PWID.  
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Removed from the introduction 
[Remove >] An estimated 970,000 of the 3.1 million PWID in this region are infected 
with HIV (Jolley, et al., 2012; Mathers, et al., 2008; United Nations Joint Programme on 
HIV and AIDS, 2013, 2014). 
[Removed] ATS were estimated to contribute two thirds of the global burden of 
stimulant dependence in 2010 and ATS use has increased in Eastern Europe, Central 
and Southeast Asia (L. Degenhardt, et al., 2014; Mehrjerdi, 2013; Mehrjerdi, et al., 
2014; Saw, et al., 2014; United Nations Office on Drugs and Crime, 2015a, 2016).  
Removed from the discussion 
Nevertheless, ATS may provide an entry point for young injectors who experiment with 
stimulant drugs and move on to inject other addictive substances (Van Ameijden, Van 
den Hoek, Hartgers, & Coutinho, 1994).
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Table 2. Characteristics of sample and by reported primary amphetamine injection in Kohtla-Järve (Estonia) and 
St. Petersburg (Russian Federation) 
 
Kohtla-Järve St. Petersburg 
CHARACTERISTICS 
DEMOGRAPHIC VARIABLES 
All(1) PWID 
Kohtla-Järve 
N 
591 
Primary  
amphetamine 
(%)(1) 
n 
195 
All(1) PWID 
St. Petersburg 
N 
811 
Primary  
amphetamine 
(%)(1) 
n 
27 
Sex         
Female 26% 155 29.7% 58 22% 180 48.2% 13 
Male 74% 434 70.3% 137 78% 631 51.9% 14 
Missing  2  0  0  0 
Age group         
< 30 years  50% 294 61.5%* 120 30% 241 74.1%* 20 
>= 30 years 50% 297 38.5% 75 70% 570 25.9% 7 
Missing  0  0  0  0 
Ethnicity         
Estonian 12% 66 12.3% 24 0% 0 0% 0 
Other 7% 43 5.1% 10 4% 36 3.7% 1 
Russian 81% 481 82.6% 161 96% 775 96.3% 26 
Missing  1  0  0  0 
Education completed         
Basic (9th grade)/vocational 80% 472 81.0% 158 58% 475 29.6%* 8 
Secondary (11th grade) 19% 116 19.0% 37 30% 243 51.9% 14 
Higher (SP only) 1% 3 0% 0 12% 93 18.5% 5 
Missing  0  0  0  0 
Living arrangements         
Unstable (hostel, dormitory, shelter) 40% 238 39.5% 77 36% 292 51.9%* 14 
Stable (own or partner’s flat/house) 60% 352 60.5% 118 64% 519 48.2% 13 
Missing  1  0  0  0 
Main income source         
irregular/illicit (SP only)  3% 15 - - 16% 134 3.7% 1 
non-regular/dependant 33% 193 38.5% 74 39% 312 37.0% 10 
regular/salaried 64% 375 61.5% 118 45% 362 59.3% 16 
Missing  8  3  3  0 
CONTEXTUAL VARIABLES         
Lifetime drug treatment         
Ever had drug treatment 55% 324 32.8%* 64 72% 582 25.9%* 7 
Never in treatment 45% 267 67.2% 131 28% 229 74.1% 20 
Missing  0  0  0  0 
Drug/substitution treatment         
Yes (12 months) 13% 75 6.7%* 13 11% 86 14.8% 4 
No  87% 516 93.3% 182 89% 724 85.2% 23 
Missing  0  0  1  0 
NSP programme (4 weeks)          
Contact with NSP 82% 451 66.7%* 124 16% 119 3.7%* 1 
No contact with NSP 18% 102 33.3% 62 84% 645 96.3% 26 
Missing  38  9  47  0 
Source of clean needle/syringes         
Other (friend, dealer, street) 5% 27 66.7%* 124 4% 30 40.7%* 11 
Pharmacist/chemist 13% 75 26.3% 49 81% 615 55.6% 15 
NSP 82% 451 7.0% 13 16% 119 3.7% 1 
Missing  38  9  47  0 
Incarceration         
Ever in prison 55% 324 30.3%* 59 34% 274 7.4%* 2 
Never in prison 45% 267 69.7% 136 66% 537 92.6% 25 
Missing  0  0  0  0 
Needles/syringes confiscated        
Had N/S confiscated 31% 404 15.9%* 31 26% 212 0% 0 
No N/S confiscated 69% 184 84.1% 164 74% 599 100% 27 
Missing  3  0  0  0 
Table 1: (1) Column percentage. Crude estimates are presented for Kohtla-Järve and St. Petersburg; adjusted 
estimates using respondent driven sampling weights (RDS-II, Volz-Heckathorn) are shown in supplementary 
material as is the number of missing observations. NSP=Needle and syringe programme. HIV= Human Immune 
deficiency Virus. (2) Drug/substitution treatment in last 12 months refers to opiate drug substitution (OST) in 
Kohtla-Järve and to detoxification (non-OST) in St Petersburg. *Statistically significant result in comparisons of 
ATS- and opioid-injectors using Pearson's Chi-squared test for proportions (p-value <0.05) or Fisher's exact when 
expected cell count is <4.  
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Table 3. Predictors of primary ATS injection in Kohtla-Järve (Estonia) and St. Petersburg (Russian Federation) 
DEMOGRAPHIC CHARACTERISTICS Kohtla-Järve - ATS injectors (n=195) St. Petersburg - ATS injectors (n=27) 
 (reference: opioid injectors) OR(1)95% CI aOR(2)95%CI OR(1)95% CI aOR(2)95%CI 
Sex 
 
 
 
 
Female 1.3(0.9-1.9) 1.3 (0.9-1.6) 3.4 (1.0-11.5) 1.7 (0.7- 4.1) 
Male ref ref ref ref 
Age group 
 
 
 
 
< 30 years  2.0 (1.3-3.3) 2.1 (1.4-3.2) 7.3 (2.6-20.3) 6.8 (2.8-16.5) 
>= 30 years ref ref ref ref 
Ethnicity 
 
 
 
 
Estonian 1.2 (0.8-1.9) 1.1 (0.6-2.1) - - 
Other 0.6 (0.2-1.8) 0.6 (0.3-1.1) 0.8 (0.1-9.2) 0.8 (0.1-11.4) 
Russian ref  ref. ref. 
Education completed 
 
 
 
 
Basic (9thgrade)/vocational 1.1 (0.6-1.8) 1.0 (0.6-1.7) 0.3 (0.05-1.7) 2.6 (1.2-6.7) 
Secondary (11th grade) ref ref 1.1 (0.4-3.2) 2.5 (0.7-9.6) 
Higher (SP only) - - ref ref 
Living arrangements     
Unstable (hostel, dorm, shelter) 0.9 (0.6-1.4) 0.9 (0.6-1.2) 2.0 (0.9-4.1) 2.2 (1.0-4.6) 
Stable (own/partner home) ref ref ref ref 
Main income source 
 
 
 
 
irregular/illicit (SP only) - - 0.2 (0.02-1.6) 0.1 (0.05-1.5) 
non-regular/dependant 1.3 (0.9 -1.7) 1.0 (0.6 -1.5) 0.7 (0.4-1.5) 0.8 (0.4-1.5) 
regular/salaried ref. ref. ref ref 
Age at first injection    
Primary ATS/Opioid 1.1 (1.1-1.2) 1.1 (1.0-1.2) 1.1 (1.0-1.3) 1.3 (1.1-1.4) 
CONTEXTUAL VARIABLES     
Lifetime drug treatment     
Ever drug treatment 0.2 (0.2-0.3) 0.3 (0.2-0.5) 0.2 (0.1-0.6) 0.2 (0.1-0.5) 
Never in treatment ref ref ref ref 
Drug/substitution treatment    
Yes (12 months) 0.4(0.2-0.7) 0.5 (0.3-0.9) 1.5 (0.4-5.8) 1.9 (0.3-12.7) 
No  ref. ref ref ref 
NSP programme (4 weeks)     
Contact with NSP 0.2 (0.1-0.3) 0.2 (0.2-0.6) 0.2 (0.05-1.0) 0.4 (0.1-2.2) 
No contact with NSP ref ref ref ref 
Source of clean needle/syringes    
Other (friend, dealer, street) 2.4 (0.7-9.9) 2.0 (0.5-7.9) 67 (8.1-544) 35 (2.7-472) 
Pharmacist/chemist 6.0 (4.1-8.6) 4.9 (3.5-6.9) 2.9 (0.6-14.2) 1.8 (0.3-9.3) 
NSP ref ref ref ref 
Incarceration     
Ever in prison 0.2 (0.1-0.3) 0.3 (0.2-0.5) 0.2 (0.1-0.3) 0.2 (0.1-0.8) 
Never in prison ref ref ref ref 
Needles/syringes confiscated    
Had N/S confiscated 0.3 (0.1-0.9) 0.3 (0.1-0.8) - Too few obs. 
No N/S confiscated ref ref   
Table 2. (1) Odds ratio (OR) with 95% confidence intervals (95% CI) refer to primary Amphetamine-Type Stimulant (ATS) versus 
opioids (reference group is “primary opioid injectors”). (2) Multivariable model for ATS was adjusted for predictors: age, sex, 
education, duration of injecting (and living arrangements in St. Petersburg). Statistically significant results at the α< 0.05 are 
marked in bold. (3) Needle/syringe programme (NSP), drug treatment and needles/syringes confiscated were adjusted for in 
models where the outcome was injecting risk. (4) Drug/substitution treatment in last 12 months refers to opiate drug 
substitution (OST) in Kohtla-Järve and to detoxification (non-OST) in St Petersburg. 
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Table 4. Association between ATS injection and injecting risk behaviours (Kohtla-Järve, St. Petersburg) 
OUTCOMES: INJECTING RISK (3)  Kohtla-Järve – ATS injectors (n=195) St. Petersburg – ATS injectors (n=27) 
 (reference: opioid injectors) OR(1)95% CI aOR(2)95%CI OR(1)95% CI aOR(2)95%CI 
Duration of injecting 
 
 
 
 
≤ 5 years 6.1 (3.8-9.6) 3.5 (1.9-6.2) 14.7 (4.2-51) 8.3 (2.2-31.6) 
> 5 years ref. ref ref. ref 
Frequency of injecting 
 
 
 
 
Daily or more 0.2 (0.1-0.5) 0.3 (0.2-0.6) 0.2 (0.1-1.0) 0.2 (0.1-0.9) 
Less than daily  ref. ref. ref. ref. 
Ever shared needles/syringes  
 
 
Yes 0.2 (0.1-0.3) 0.3 (0.2-0.5) 0.05 (0.03-0.1) 0.1 (0.1-0.2) 
No ref. ref. ref. ref. 
Injected w/used needles/syringes   
 
 
Yes 0.5 (0.1-1.6) 0.5 (0.2-1.5) 0.1 (0.05-0.3) 0.2 (0.1-0.6) 
No ref. ref. ref. ref. 
Filled from working syringe (back-loaded)  
 
 
Yes 0.4 (0.2-1.2) 0.4 (0.2-0.8) 0.1 (0.1-0.3) 0.2 (0.1-0.5) 
No ref. ref. ref. ref. 
Shared drug paraphernalia  
 
 
Yes 0.5 (0.2-1.3) 0.5 (0.3-1.2) 0.2 (0.1-0.3) 0.3 (0.1-0.6) 
No ref. ref. ref. ref. 
Any polydrug use (any)  
 
 
≥ 2 drugs 2.2 (1.5-3.4) 2.0 (1.1-3.5) 0.7 (0.4-1.2) 0.7 (0.4-1.2) 
Main drug only ref. ref. ref. ref. 
Table 3. (1) Odds ratio (OR) with 95% confidence intervals (95% CI) refer to primary Amphetamine-Type Stimulant (ATS) versus 
opioids (reference group). (2) Multivariable models were adjusted for age, sex, education, duration of injecting, needle/syringe 
programme (NSP), drug/substitution treatment, needles/syringes (N/S) confiscated (and living arrangements in St. 
Petersburg). Statistically significant results at the α< 0.05 are marked in bold. (3) Injecting risk in the last 4 weeks. 
 
 
 
Table 5. Associations between ATS injection and sexual risk behaviours (Kohtla-Järve, St. Petersburg) 
OUTCOMES: SEXUAL RISK (3) Kohtla-Järve - ATS injectors (n=195) St. Petersburg - ATS injectors (n=27) 
 (reference: opioid injectors) OR(1)95% CI aOR(2)95%CI OR(1)95% CI aOR(2)95%CI 
Any sex in 6 months 
 
   
Yes 1.8 (1.0-3.3) 1.7 (0.9-3.3) 1.8 (0.8-3.9) 1.6 (0.7- 3.8) 
No ref. ref ref. ref 
Regular sex partner injects    
Yes 0.7 (0.4-1.1) 0.8 (0.5-1.9) 0.8 (0.2-3.3) 0.8 (0.2- 3.0) 
No ref. ref ref. ref 
Casual sex partner injects 
 
   
Yes 1.1 (0.8-1.5) 1.8 (0.5-7.1) 0.5 (0.1-2.6) 0.4 (0.1-2.2) 
No ref. ref ref. ref 
Was ever paid for sex  
 
   
Yes 1.3 (0.9-1.8) 2.6 (1.2-5.7) 12.2 (3.7-40) 5.2 (1.0-27) 
No ref. ref ref. ref 
Multiple sex partners 
 
   
>= 2 sex partners 0.8 (0.4-1.6) 0.7 (0.3-1.5) 0.9 (0.5-1.8) 0.7 (0.3-1.6) 
one sex partner Ref ref ref ref 
Condom with regular partner     
Yes (consistent) 0.9 (0.7-1.4) 1.0 (0.7-1.4) 1.9 (0.4-4.6) 1.5 (0.5-4.5) 
No ref. ref ref ref 
Condom with casual partner    
Yes (consistent) 1.4 (0.6-3.0) 1.2 (0.6-2.6) 10.4 (1.9-57) 8.0 (1.1-60) 
No ref. ref ref ref 
Table 4:(1) Odds ratio (OR) with 95% confidence intervals (95% CI) refer to primary Amphetamine-Type Stimulant (ATS) versus 
opioids (reference group). (2) Multivariable models were adjusted for age, sex, education, duration of injecting, needle/syringe 
programme (NSP), drug /substitution treatment, needles/syringes (N/S) confiscated (and living arrangements in St. 
Petersburg). Statistically significant results at the α< 0.05 are marked in bold. (3) Sexual risk in the last 6 months. 
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Table 6. Associations between ATS injection and serological markers (Kohtla-Järve, St. Petersburg) 
SEROLOGICAL MARKERS (3) Kohtla-Järve - ATS injectors (n=195) St. Petersburg - ATS injectors (n=27) 
(reference: opioid injectors) OR(1)95% CI aOR(2)95%CI OR(1)95% CI aOR(2)95%CI 
HIV status     
Positive 0.4 (0.3-0.6) 0.6 (0.5-0.8) 0.2 (0.1-0.4) 0.3 (0.1-0.7) 
Negative ref ref ref ref 
Hepatitis C     
HCV reactive 0.3 (0.2-0.4) 0.5 (0.3-0.6) Not collected Not collected 
Non-reactive ref. ref - - 
HSV-2 status     
Positive 1.0 (0.6-1.6) 1.2 (0.7-2.0) Not collected Not collected 
Negative ref. ref - - 
Table 5: (1) Odds ratio (OR) with 95% confidence intervals (95% CI) refer to primary Amphetamine-Type Stimulant (ATS) versus 
opioids (reference group). (2) Multivariable models were adjusted for age, sex, education, duration of injecting, needle/syringe 
programme (NSP), drug /substitution treatment, needles/syringes (N/S) confiscated (and living arrangements in St. 
Petersburg). Statistically significant results at the α< 0.05 are marked in bold. HIV= Human Immune deficiency Virus. 
HCV=Hepatitis C and HSV-2=Herpes Simplex Virus. 
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